Stoke Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Stoke Therapeutics

14/11/2022 14:37

* Stoke Therapeutics Inc  STOK.OQ  reported a quarterly
adjusted
loss of 66 cents​​ per share for the quarter ended in September.
The mean expectation of ten analysts for the quarter was for a
loss of 68 cents per share.
    * Revenue was $2.91 million​; analysts expected $2.45
million. 
    * Stoke Therapeutics Inc's reported EPS for the quarter was
a loss
of 66 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Stoke Therapeutics Inc shares had fallen by 2.7% this
quarter and lost 47.9% so far this year.
    * The company reported a quarterly loss of $26.11 million.
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $50.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:37 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.68          -0.66          Beat
 Jun. 30 2022      -0.69          -0.63          Beat
 Mar. 31 2022      0.36           -0.66          Missed
 Dec. 31 2021      -0.62          -0.66          Missed